Dr. Fatima Cody Stanford, Associate Professor of Medicine and Pediatrics at Harvard Medical School, Joins Clearmind Medicine's Scientific Advisory Board
2023年7月11日 - 9:30PM
Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY)
(“Clearmind” or the "Company"), a biotech company focused on
discovery and development of novel psychedelic-derived therapeutics
to solve major under-treated health problems, today announced the
appointment of Dr. Fatima Cody Stanford, Associate Professor of
Medicine at Massachusetts General Hospital and Harvard Medical
School, to its Scientific Advisory Board. Dr. Stanford brings
extensive expertise in the treatment of obesity, making her a
valuable addition to Clearmind's mission of transforming the
treatment landscape for obesity by advancing MEAI as a potential
treatment.
Dr. Stanford is currently associated with
Massachusetts General Hospital and is an Associate Professor of
Medicine and Pediatrics at Harvard Medical School, where she serves
as an educator, researcher, and policy maker. Her extensive
academic background includes a Bachelor of Science and Master of
Public Health from Emory University, a MD from the Medical College
of Georgia School of Medicine, a Masters of Public Administration
from the Harvard Kennedy School of Government and a MBA from the
Quantic School of Business and Technology. Dr. Stanford completed
her Obesity Medicine & Nutrition Fellowship at Massachusetts
General Hospital and Harvard Medical School, further enhancing her
expertise in the field.
With a career dedicated to bridging the gaps
between medicine, public health, and policy, Dr. Stanford has
become a sought-after expert in obesity medicine, both nationally
and internationally. Her unique perspective and multidisciplinary
approach are aligned with Clearmind Medicine's vision to develop
innovative treatments for addiction and address the underlying
causes, including obesity.
"We are delighted to welcome Dr. Fatima Cody
Stanford to our Scientific Advisory Board. Her diverse experience,
combined with Clearmind's commitment to advancing psychedelic-based
therapies, holds great promise for individuals struggling with
metabolic syndrome and obesity. We look forward to leveraging her
expertise as we continue to develop innovative treatments that
address obesity, which is considered by many to be a true epidemic
of the 21st century." said Clearmind’s Chief Executive Officer, Dr.
Adi Zuloff-Shani.
In a pre-clinical study (see the Company’s press
release of January 5, 2023) conducted at the Hebrew University of
Jerusalem as part of a collaboration established with the
university’s technology transfer company, Yissum, that was led by
Prof. Joseph Tam, a member of our Scientific Advisory Board,
demonstrated that animals with obesity treated with MEAI exhibited
an increased energy expenditure, as well as better fat utilization
and weight loss of 20%, while also reducing their overall fat mass
and preserving lean body mass. No effect on motivation and
well-being was observed. Additionally, MEAI treatment yielded
normalization of insulin levels, improved glucose tolerance, as
well as reduced fat and triglyceride accumulation in the liver.
These results were significantly better than those obtained in the
high-fat, untreated group. Furthermore, a significant reduction in
sucrose preference was observed following administration of MEAI
for two days, supporting the notion that it can dampen the hedonic
value of rewarding stimuli. Thus, MEAI may be beneficial for the
treatment of compulsive reward-seeking behavior or excessive
consumption of sweet foods.
The study was discussed in a recent virtual webinar hosted by
Professor Tam,- which is available here.
About Clearmind Medicine Inc.
Clearmind is a psychedelic pharmaceutical
biotech company focused on the discovery and development of novel
psychedelic-derived therapeutics to solve widespread and
underserved health problems, including alcohol use disorder. Its
primary objective is to research and develop psychedelic-based
compounds and attempt to commercialize them as regulated medicines,
foods or supplements.
The Company’s intellectual property portfolio
currently consists of fourteen patent families. The Company intends
to seek additional patents for its compounds whenever warranted and
will remain opportunistic regarding the acquisition of additional
intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on
Nasdaq and the Canadian Securities Exchange under the symbol "CMND"
and the Frankfurt Stock Exchange under the symbol “CWY.”
For further information
visit: https://www.clearmindmedicine.com or contact:
Investor Relations invest@clearmindmedicine.com Telephone: (604)
260-1566 US: CMND@crescendo-ir.com
General Inquiries Info@Clearmindmedicine.com
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act and other securities laws. Words such as “expects,”
“anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates”
and similar expressions or variations of such words are intended to
identify forward-looking statements. For example, the Company is
using forward-looking statements when it discusses collaboration
with SciSparc and its intent to further investigate the effect of
the combination of MEAI and PEA for treating obesity and metabolic
syndrome. Forward-looking statements are not historical facts, and
are based upon management’s current expectations, beliefs and
projections, many of which, by their nature, are inherently
uncertain. Such expectations, beliefs and projections are expressed
in good faith. However, there can be no assurance that management’s
expectations, beliefs and projections will be achieved, and actual
results may differ materially from what is expressed in or
indicated by the forward-looking statements. Forward-looking
statements are subject to risks and uncertainties that could cause
actual performance or results to differ materially from those
expressed in the forward-looking statements. For a more detailed
description of the risks and uncertainties affecting the Company,
reference is made to the Company’s reports filed from time to time
with the Securities and Exchange Commission (“SEC”), including, but
not limited to, the risks detailed in the Company’s annual report
on Form 20-F filed with the SEC on February 6, 2023.
Forward-looking statements speak only as of the date the statements
are made. The Company assumes no obligation to update
forward-looking statements to reflect actual results, subsequent
events or circumstances, changes in assumptions or changes in other
factors affecting forward-looking information except to the extent
required by applicable securities laws. If the Company does update
one or more forward-looking statements, no inference should be
drawn that the Company will make additional updates with respect
thereto or with respect to other forward-looking statements.
References and links to websites have been provided as a
convenience, and the information contained on such websites is not
incorporated by reference into this press release. Clearmind is not
responsible for the contents of third-party websites.
Clearmind Medicine (NASDAQ:CMND)
過去 株価チャート
から 4 2024 まで 5 2024
Clearmind Medicine (NASDAQ:CMND)
過去 株価チャート
から 5 2023 まで 5 2024